(PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip

(PQA4) 通过 V-Chip 进行肝细胞癌暴露风险即时检测

基本信息

批准号：
8590772
负责人：
Lidong Qin
金额：
$ 53.45万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-10 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8590772
关键词：
Aflatoxins Alcohol consumption Antibodies Area Bedside Testings Biological Biological Assay Biological Markers Blood Blood Tests Blood specimen Buffers Case-Control Studies Chronic Cirrhosis Clinical Communication Computers Data Decision Making Detection Development Devices Diabetes Mellitus Diet Drops Enzyme-Linked Immunosorbent Assay Epidemiologic Studies Epidemiology Ethnic group Exhibits Exposure to Fingers Future Geographic Locations Glass Grant Guidelines HCV and Aflatoxin Hepatitis B Hepatitis B Virus Hepatitis C virus Home environment Hospitals Hydrogen Peroxide Image Incidence Individual Iron Life Style Liquid substance Low income Mass Spectrum Analysis Measurement Measures Medical Medicine Methods Microfabrication Microfluidics Modeling Monitor Obesity Oxygen Patients Persons Pregnancy Prevention strategy Primary carcinoma of the liver cells Probability Production Race Reaction Reader Recycling Reporting Resources Risk Risk Assessment Risk Factors Risk Reduction Running Side Slide Smoking Solutions Specialist Spottings Technology Telemedicine Telephone Testing Training Viral hepatitis Visit base cancer risk case control catalase computerized data processing cost cost effective high risk improved instrument instrumentation meetings miniaturize modifiable risk new technology operation point of care public health relevance rapid detection research clinical testing synergism virus development

项目摘要

DESCRIPTION (provided by applicant): (PQA4) Point-of-Care Test of Exposure to Hepatocellular Carcinoma Risk by V-Chip Underlying mechanisms for synergisms of HCC risks may provide efficient and accurate HCC prevention strategies for high-risk individuals. People exposed to environmental or life-style risk factors simultaneously exhibit the increased incidence of HCC development. However, most of the burden of HCC is associated with the group of people with low income, with the highest incidence rates reported in regions where infection with hepatitis B virus (HBV) is endemic. Therefore, developing an accurate, quantitative, and also low-cost technology for the rapid detection of biomarkers is required for HCC risk assessment. Herein, we propose an ELISA-based new technology platform, the multiplexed volumetric bar-chart chip (V- Chip), to detect biomarkers in blood samples. The proposed V-Chip is based on microfluidics technology. The integrated volumetric readouts, based on measurements of oxygen generated by a reaction between catalase and hydrogen peroxide, allow rapid ELISA quantitation of biomarkers and provide visualized bar charts on V- Chip without any assistance from instruments, data processing, or graphic plotting. The accuracy of the V-Chip will be validated in HCC cases and controls using standard ELISA assay. Based on epidemiological risk factors and biomarkers on V-chip, we will develop a risk prediction model to predict a person's probability of developing HCC in the next 5 and 10 years based on current risk profiles as well as risk reduction if the patient's modifiable risk factors change. This risks prediction V chip is particularly suitable for the application in resource-limited areas with higher HCC incidence. Patients can use V-Chip in home and personally monitor cirrhosis or HBV/HCV development by themselves, which may bring potential HCC patients to hospital and professionals earlier and thus greatly reduced the costs and risks of HCC.

描述（由申请人提供）：（PQA4）通过 V 芯片进行肝细胞癌风险暴露的护理点测试 HCC 风险协同作用的基本机制可以为高风险个体提供有效且准确的 HCC 预防策略。暴露于环境或生活方式危险因素的人同时表现出 HCC 发病率增加。然而，大部分 HCC 负担与低收入人群有关，在乙型肝炎病毒 (HBV) 感染流行的地区报告的发病率最高。因此，HCC风险评估需要开发一种准确、定量且低成本的生物标志物快速检测技术。在此，我们提出了一种基于 ELISA 的新技术平台，即多重体积条形图芯片（V-Chip），用于检测血液样本中的生物标志物。所提出的 V-Chip 基于微流体技术。集成的体积读数基于过氧化氢酶和过氧化氢之间反应产生的氧气测量，允许对生物标记物进行快速 ELISA 定量，并在 V-Chip 上提供可视化条形图，无需任何仪器、数据处理或图形绘制的帮助。 V-Chip 的准确性将使用标准 ELISA 测定在 HCC 病例和对照中进行验证。基于流行病学风险因素和V芯片上的生物标志物，我们将开发一个风险预测模型，根据当前的风险状况预测一个人在未来5年和10年内患HCC的概率，并根据患者可改变的风险因素降低风险改变。这有预测V的风险该芯片特别适合在资源有限、HCC发病率较高的地区应用。患者可以在家中使用V-Chip，亲自监测肝硬化或HBV/HCV发展情况，这可以将潜在的HCC患者更早地带到医院和专业人士处，从而大大降低HCC的成本和风险。